OTTAWA (Reuters) – Canada presented a real-time review of AstraZeneca’s knowledge and the COVID-19 vaccine at Oxford University on Friday, the newest country to advance its approval process.
As the war on the coronavirus pandemic intensifies, with an increase in infections and deaths, the Canadian Department of Health said it won its first application for permission for the vaccine on Thursday.
The purpose of an ongoing review is to speed up the procedure and, last month, Canada’s Minister of Health Patty Hajdu signed an ordinance that allows companies preparing vaccines to submit data and knowledge on protection and efficacy as they become available.
The European Union fitness regulator also presented an ongoing review of the first batch of vaccine knowledge that AstraZeneca is running on Thursday.
Canada’s fitness regulator will first compare preclinical knowledge of studies conducted through Oxford University, and then compare preclinical and clinical studies to available knowledge, the British drug manufacturer said, welcoming the decision.
The University of Oxford did not respond to requests for comment.
The Canadian branch will not allow this or any other vaccine until it has obtained the mandatory evidence to help its safety, efficacy and quality, he said.
It is also in talks with various vaccine brands and said that any company can request the use of the ongoing review process.
The news comes at most one month after several global trials of the vaccine were suspended due to an unexplained disease in a participant. While peak studies have resumed, trials in the US have resumed. But it’s not the first time They are still on hold as regulators have expanded their investigation.
Last week, Canada agreed to purchase up to 20 million doses of the candidate vaccine, one of many agreements it has signed to protect some three hundred million possible vaccines, as the global number of coronavirus deaths exceeds one million.
Called AZD1222 or ChAdOx1 nCoV-19, the AstraZeneca vaccine is a leader in the race for inoculation of others who oppose COVID-19. Other complex vaccine applicants come with Pfizer, Moderna and Sinovac.
(Information through Steve Scherer in Ottawa; additional information via Pushkala Aripaka in Bengaluru and Alistair Smout in London; Written through Josephine Mason in London; Edited through Mark Potter, Alexander Smith and Louise Heavens)
Subscribe
Sign up for our news explosion.